Dear Readers,
The Healthcare Sector continues to be fertile ground for antitrust issues, whether in the case of hospital or pharmaceutical mergers (vertical, cross-market, etc.), pay for delay issues, patent settlements, or parallel exports, etc.
CPI is pleased to present out latest Antitrust Chronicle® focusing on some of these hotly discussed topics in the Healthcare Sector in the United States and Europe.
The DOJ’s Antitrust Division remains focused on anticompetitive practices in the Healthcare Sector. At the ABA Healthcare Conference on May 17, 2018, Barry Nigro, Deputy Assistant Attorney General, stated: “Because competition benefits consumers in so many ways, antitrust enforcement will continue to play an outsized role in healthcare.” Mr. Nigro continued: “Protecting and fostering competition in this space is a responsibility that we at the Antitrust Division take very seriously, and, because of that, antitrust enforcement in healthcare will continue to be a high priority for the Division.”
The same holds true in Europe. The European Commission regularly monitors business practices in the pharmaceutical, health services, and medical devices markets. The Commission’s main enforcement actions in antitrust and mergers in the pharmaceutical sector are set out in its “Report on competition enforcement in the pharmaceutical sector (2009-2017).” The Report was drawn up in cooperation with the national competition authorities and explains how competition autho
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.245
Please verify email or join us
to access premium content!
